trial · primary record
Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg
Peripheral T-Cell Lymphoma Refractory
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 25 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Rate of complete response to up to 6 cycles of combination zilovertamab vedotin and lenalidomide |
| Registry ID | NCT07913594 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:52.137Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07913594
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.